HIGH-DOSE SUBLINGUAL ALLERGEN IMMUNOTHERAPY: ADVISABILITY AND SAFETY



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Efficacy of the allergen immunotherapy (ait) in the treatment of allergic rhinitis and asthma has been proved in many studies and systematic reviews. Higher safety profile of sublingual ait (slit) relative subcutaneous ait (sCit) defines preferences of slit. although the results of the first study of slit were published about 25 years ago and a lot of allergenic products for slit appeared during this period, poor evidence base and a lack of direct comparative controlled studies on the efficacy of slit vs sCit support debate about what way of allergen administration is more effective. it is possible, that lower efficacy of slit showed in earlier studies explains for the use of regimes with low daily and cours doses of allergens. in a recent review of the eaaCi it was shown the dosedependent therapeutic effect of ait, and was noted that an increase of the maintenance allergen dose while sCit increases the risk of adverse events, vs high doses slit demonstrates good safety profile with a significant increase of efficacy. it is possible that future studies using high doses of standardized allergens for slit will show not only more high profile of slit safety, but also its higher efficacy vs sCit.

Full Text

Restricted Access

About the authors

O M KURBACHEVA

Institute of Immunology

Moscow, Russia

K S PAVLOVA

Institute of Immunology

Moscow, Russia

References

  1. Гущин И.С., Курбачева О.М. Аллергия и аллерген-специ- фическая иммунотерапия. М., «Фармарус Принт Медиа», 2010, 228 с.
  2. Bousquet J., Lockey R., Malling H.J. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998, v. 53, p. 1-42.
  3. Eifan A.O., Calderon M.A., Durham S.R. Allergen immuno- therapy for house dust mite: clinical efficacy and immunolog- ical mechanisms in allergic rhinitis and asthma. Expert. Opin. Biol. Ther. 2013, v. 13, p. 1543-1556.
  4. Radulvic S., Calderon M.A., Wilson D., Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst. Rev. 2010, Issue 12, CD002893.
  5. Akdis M., Schmidt-Weber C., Jutel M. et al. Mechanisms of allergen immunotherapy. Allergy Clin. Immunol Int. J. World Allergy Org. 2004, v. 16, p. 65-69.
  6. Ozdemir C. An immunological overview of allergen specific immunotherapy - subcutaneous and sublingual routes. Ther. Adv. Resp. Dis. 2009, v. 3, p. 253-262.
  7. Akdis M., Verhagen J., Taylor A. et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T-regulatory 1 and T-helper 2 cells. J. Exp. Med. 2004, v. 199, p. 1567-1575.
  8. Francis J.N., Till S.J., Durham S.R. Induction of IL-10+С- D4+CD25+ T-cells by grass pollen immunotherapy. J. Allergy Clin. Immunol. 2003, v. 11, p. 1255-1261.
  9. Novembre E., Galli E., Landi F. et al. Coseasonal sublingual immunotherapy reduces the development of asthma in chil- dren with allergic rhinoconjunctivitis. J. Allergy Clin. Immu- nol. 2004, v. 114, p. 851-857.
  10. Pichler C.E., Marquardsen A., Sparholt S. et al. Specific immunotheraрy with Dermatophagoides pteronyssinus and D. farina results in decreased bronchial hyperreactivity. Allergy. 1997, v. 52, p. 274-283.
  11. Zielen S., Kardos P., Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J. Allergy Clin. Immunol. 2010, v. 126, p. 942-949.
  12. Di Rienzo V., Marcucci F., Pucinelli P. et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin. Exp. Allergy. 2003, v. 33, p. 206-210.
  13. Van Ree R., Chapman M.D., Ferreira F. et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quan- tification. Allergy 2008, v. 63, p. 310-326.
  14. Larenas-Linnemann D., Esch R., Plunkett G. et al. Main- tenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units. Ann. Allergy Asthma Immunol. 2011, v. 107, p. 448-458.
  15. Chapman M.D., Ferreira F., Villalba M. et al. The European Union CREATE project: a model for international standard- ization of allergy diagnostics and vaccines. J. Allergy Clin. Immunol. 2008, v. 122, p. 882-889.
  16. Calderon M.A., Larenas D., Kleine-Tebbe J. et al. European academy of allergy and clinical immunology task force report on ‘dose-response relationship in allergen-specific immuno- therapy’. Allergy. 2011, v. 66, p. 1345-1359.
  17. Didier A., Malling H.J., Worm M. et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J. Allergy Clin. Immunol. 2007, v. 120, p. 1338-1345.
  18. Durham S.R., Yang W.H., Pedersen M.R. et al. Sublingual immunotherapy with once-daily grass allergen tablets: a ran- domized controlled trial in seasonal allergic rhinoconjuncti- vitis. J. Allergy Clin. Immunol. 2006, v. 117, p. 802-809.
  19. Skoner D., Gentile D., Bush R. et al. Sublingual immuno- therapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J. Allergy Clin. Immunol. 2010, v. 125, p. 660-666.
  20. Valovirta E., Jacobsen L., Ljorring C. et al. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy. 2006, v. 61, p. 1177-1183.
  21. Wahn V., Tabar A., Kuna P. et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2009, v. 123, p. 160-166.
  22. Didier A., Worm M., Horak F. et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunother- apy tablets in patients with grass pollen-induced rhinoconjunc- tivitis. J. Allergy Clin. Immunol. 2011, v. 128, p. 559-566.
  23. Worm M., Rak S., De Blay F. et al. Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: result of a double-blind, placebo-controlled study. Clinical and Translational Allergy. 2014, v. 4, p. 1-11.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2014



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies